Author

P. Exman

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 1 Organism:human· 1 Approach:statistical model· 1 Assay:whole-exome sequencing· 1

Frequent Co-Authors

A. G. Waks· 1 shared A. Regev· 1 shared D. E. Root· 1 shared E. P. Winer· 1 shared F. Federica Piccioni· 1 shared J. Chung· 1 shared J. E. Buendia-Buendia· 1 shared J. G. Kusiel· 1 shared

Activity by Year

2019-2019 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

A. G. Waks

Mutual co-authors in cluster

Author profile →

1 paper

Recent·Most cited

Acquired FGFR and FGF alterations confer resistance to estrogen receptor (ER) targeted therapy in ER+ metastatic breast cancer

P. Mao, O. Cohen, K. J. Kowalski, J. G. Kusiel, J. E. Buendia-Buendia, M. S. Cuoco, P. Exman, S. A. Wander, A. G. Waks, U. Nayar, J. Chung, S. Freeman, O. Rozenblatt-Rosen, V. A. Miller, F. Federica Piccioni, , N. Wagle

This study identifies FGFR and FGF pathway alterations as acquired resistance mechanisms to ER-targeted therapy in ER+ metastatic breast cancer and suggests targeted inhibitors as potential treatments.

bioRxiv · Oct 7, 2019Cancer Biology